文献速递心脑血管急症重症综合管理与镇静镇痛

乙酰唑胺通过抑制AQP4 mRNA表达减轻缺血性卒中脑水肿

Acetazolamide Alleviate Cerebral Edema Induced by Ischemic Stroke Through Inhibiting the Expression of AQP4 mRNA.
PubMed 文献 · Neurocrit Care · 2021-07-23
一句话结论大鼠实验显示乙酰唑胺35 mg/kg/day腹腔注射可降低缺血性卒中后脑含水量并改善脑功能,机制与抑制AQP4表达相关。

该研究在大鼠双侧颈动脉结扎(2-VO)缺血性卒中模型中,将SD大鼠随机分为假手术+生理盐水组、假手术+AZA组、AZA干预组和非干预组,并按缺血时间6小时、1天、3天、5天、7天分亚组。干预组腹腔注射AZA 35 mg/kg/day。结果显示缺血卒中后脑含水量及AQP4蛋白和mRNA表达显著升高,AZA给药降低了脑含水量、改善了缺血性卒中导致的脑功能障碍,并明显降低AQP4蛋白和mRNA表达。结论认为AQP4表达与缺血性卒中脑水肿密切相关,AZA通过降低AQP4 mRNA表达减轻脑水肿和脑病理损伤。

要点

  • 在大鼠2-VO缺血性卒中模型中,AZA干预组给予腹腔注射35 mg/kg/day,可降低脑含水量并改善脑功能障碍。
  • 缺血性卒中后脑组织AQP4蛋白和mRNA表达显著高于假手术组,AZA给药后明显降低AQP4蛋白和mRNA表达。
  • 该研究为动物实验,尚不能将AZA 35 mg/kg/day腹腔注射方案直接外推为急诊/ICU缺血性卒中患者的临床推荐剂量。
  • 研究按缺血后6小时、1天、3天、5天、7天五个时间点观察,但原文未报告各时间点具体数值或统计量。
  • 原文未提供AZA在人体缺血性卒中脑水肿中的疗效或安全性数据,临床决策不能仅凭此大鼠结果改变实践。

适用人群与场景

  • SD大鼠双侧颈动脉结扎(2-VO)缺血性卒中模型;分为假手术+生理盐水组、假手术+AZA组、AZA干预组和非干预组,每组按缺血6小时、1天、3天、5天、7天分亚组。
  • 原文未提及人类适用人群、排除人群或急诊/ICU场景。

诊断标准与关键阈值

  • 原文未提及临床诊断标准或关键阈值;动物模型采用双侧颈动脉结扎(2-VO)法建立脑梗死模型。

处置流程与药物剂量

  • AZA干预组大鼠给予腹腔注射AZA 35 mg/kg/day;原文未提及给药频次拆分、疗程起止或目标值。
  • 原文未提及人体给药途径、剂量、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为大鼠实验;样本量原文未提及;单中心信息原文未提及。
  • 缺血性卒中大鼠出现显著脑病理损伤;干预组和非干预组脑含水量、AQP4蛋白和mRNA表达均显著高于假手术组。
  • AZA给药降低脑含水量,并改善缺血性卒中导致的脑功能障碍。
  • AZA明显降低缺血性卒中后大鼠脑内AQP4蛋白和mRNA表达。

证据类型、等级与局限

  • 证据类型为动物实验(大鼠),原文未给出证据等级或推荐强度。
  • 局限:动物模型、样本量原文未提及、单中心信息原文未提及,结果不能直接外推至人类临床。

对床旁实践的改变

  • 该大鼠实验提示AZA可能通过抑制AQP4表达减轻缺血性卒中脑水肿,但原文未提供人体数据,不能据此改变急诊/ICU对缺血性卒中脑水肿的现有临床做法。
  • 适用与不适用人群:仅适用于该大鼠2-VO模型;原文未提及人类适用或排除人群。
  • 常见陷阱:不可将动物实验中的AZA 35 mg/kg/day腹腔注射方案直接用作人类推荐剂量;原文未报告临床疗效或安全性终点。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: We want to investigate the effect of aquaporin-4 (AQP4) on cerebral edema induced by ischemic stroke in rats and explore whether inhibiting the expression of AQP4 through acetazolamide (AZA) could attenuate brain edema and protect cerebral function.

METHODS: The Sprague Dawley (SD) rats were randomly divided into four groups: sham + saline group, sham + AZA group, AZA intervention group, and nonintervention group. Each group was divided into five subgroups according to the time of cerebral ischemia (6 h, 1 day, 3 days, 5 days, and 7 days). The model of cerebral infarction in rats was adopted by means of the bilateral carotid arteries ligation (2-VO) method. The rats in intervention group were given intraperitoneal injection of AZA (35 mg/kg/day). Hematoxylin-eosin staining was performed for pathological analysis of the infarcted area. The brain water content was calculated to evaluate the degree of brain edema. The messenger RNA (mRNA) and protein expressions of AQP4 in the brain were measured by quantitative real-time polymerase chain reaction and immunohistochemistry, respectively.

RESULTS: Significant cerebral pathological damages were found in ischemic stroke rats. The brain water content, protein, and mRNA expression of AQP4 of the intervention and nonintervention groups were markedly higher than those of the sham groups. By contrast, AZA administration reduced the brain water content, whereas improved cerebral dysfunction was induced by ischemic stroke. Moreover, AZA obviously reduced the protein and mRNA expression of AQP4 after ischemic stroke in rats' brains.

CONCLUSIONS: The expression of AQP4 was closely related to cerebral edema induced by ischemic stroke. Decreasing the expression of AQP4 mRNA by AZA administration can effectively relieve cerebral edema and decrease cerebral pathological damage.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Hao JQ, He XY, Yang X, et al. Acetazolamide Alleviate Cerebral Edema Induced by Ischemic Stroke Through Inhibiting the Expression of AQP4 mRNA. Neurocrit Care. 2021. PMID: 34302276. doi:10.1007/s12028-021-01261-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。